Acellular pertussis vaccines for use among infants and young children

Bibliography

• EHRETH J: The global value of vaccination. Vaccine (2003) 21(7-8):596–600.
   PubMed Web of Science ®Google Scholar
• MARSHALL GS: The vaccine handbook. A practical guide for clinicians. Lippincott Williams & Wilkins, Philadelphia, USA (2004):71–78.
   Google Scholar
• TOZZI AE, RAVA L, CIOFI DEGLI ATTI ML, SALMASO S, and PROGRETTO PERTOSSE WORKING GROUP: Clinical presentation of pertussis in unvaccinated and vaccinated children in the first six years of life. Pediatrics (2003) 112 (5):1069–1075.
   PubMedGoogle Scholar
• LIESE JG, RENNER C, STOJANOV S, BELOHRADSKY BH, and the MUNICH VACCINE STUDY GROUP: Clinical and epidemiological picture of B. pertussis and B. parapertussis infections after introduction of acellular pertussis vaccines. Arch. Dis. Child. (2003) 88(8):684–687.
   Google Scholar
• HEININGER U, STEHR K, SCHMITT-GROHE S et al: Clinical characteristics of illness caused by Bordetella parapertussis compared with illness caused by Bordetella pertussis. Pediatr. Infect. Dis. J. (1994) 13(4):306–309.
   PubMedGoogle Scholar
• GIL A, OYAGOEZ I, CARRASCO P, GONZALEZ A: Hospital admissions for pertussis in Spain, 1995-1998. Vaccine (2001) 19(32):4791–4794.
   PubMedGoogle Scholar
• CROWCROFT NS, BOOY R, HARRISON T et al.: Severe and unrecognised: pertussis in UK infants. Arch. Dis. Child. (2003) 88(9):802–806.
   PubMed Web of Science ®Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Pertussis - United States, 1997-2000. MMWR Morb. Mortal. Wkly. Rep. (2002) 51(4):73–76.
   PubMedGoogle Scholar
• •Surveillance data for pertussis incidence and effectiveness of pertussis vaccination in the US during the last few years.
   Google Scholar
• BALTIMORE RS: Bronchitis, bronchiolitis, and pertussis syndrome. In: Pediatric Infectious Diseases. Principles and Practice. Jenson HB, Baltimore RS (Eds), WB Saunders Company, Philadelphia, USA (2002)779–793.
   Google Scholar
• MILLER DL, ALDERSLADE R, ROSS EM: Whooping coughand whooping cough vaccine: the risks and benefits debate. Epidemiol Rev (1982) 4:1–24.
   PubMed Web of Science ®Google Scholar
• FINE PE, CLARKSON JA: Reflections on the efficacy of pertussis vaccines. Rev Infect. Dis. (1987) 9(5):866–883.
   PubMedGoogle Scholar
• CAMPINS-MARTI M, MORAGA-LLOP FA: Tos ferina. Situación epidemiológica y nuevas estrategias de prevención. Vacunas (2002) 3(3):108–113.
   Google Scholar
• JEFFERSON T, RUDIN M, DIPIETRANTONJ C: Systematic review of the effects of pertussis vaccines in children. Vaccine (2003) 21(17-18):2003–2014.
   PubMed Web of Science ®Google Scholar
• •A comprehensive systematic review about efficacy and safety of whole-cell and acellular pertussis vaccines in children.
   Google Scholar
• CHERRY JD: The science and fiction of the 'resurgence' of pertussis. Pediatrics (2003) 112 (2):405–406.
   PubMed Web of Science ®Google Scholar
• SCHWARTZ B, ORENSTEIN WA: Vaccination policies and programmes. The federal governments's role in making the system work. Primary Care (2001) 28(4):697–711.
   Google Scholar
• CAMPINS-MARTI M, CHENG HK, FORSYTH K et al.: Recommendations are needed for adolescent and adult pertussis immunization: rationale and strategies for consideration. Vaccine (2001) 20(5-6):641–646.
   PubMedGoogle Scholar
• VAN BUYNDER PG, OWEN D, VURDIEN JE, ANDREWS NJ, MATTHEWS RC, MILLER E: Bordetella pertussis surveillance in England and Wales:1995-7. Epidemiol Infect. (1999) 123(3):403–411.
   PubMed Web of Science ®Google Scholar
• NATIONAL ADVISORY COMMITTEE ON IMMUNIZATION (NACI): Prevention of pertussis in adolescents and adults. CCDR (2003) 29(5-6):1–9.
   Google Scholar
• WORLD HEALH ORGANIZATION (WHO): Regional Office for Europe. Health 21: the health for all policy framework for the WHO European Region. European Health for All Series No. 6 (1999).
   Google Scholar
• JENKINSON D: Duration of effectiveness of pertussis vaccine. Br. Med. J. (1988) 296(6622):612–614.
   PubMedGoogle Scholar
• GORDON JE, HOOD HI: Whooping cough and its epidemiological anomalies. Am. J. Med. Sci. (1951) 222:333–361.
   PubMed Web of Science ®Google Scholar
• MADSEN T: Vaccination against whooping cough. JAMA (1933) 101:187–188.
   Google Scholar
• EDWARDS KM: Acellular pertussis vaccines - a solution to the pertussis problem?' Infect. Dis. (1993) 168(1):15–20.
   Google Scholar
• SATO Y, KIMURA M, FUKUMI H: Development of a pertussis component vaccine in Japan. Lancet (1984) 1(8369):122–126.
   PubMed Web of Science ®Google Scholar
• GARCIA SAINZ JA, ROMERO AVILA T, RUIZ ARRIAGA A: Characterization and detoxification of an easily prepared acellular pertussis vaccine. Antigenic role of the A promoter of pertussis toxin. Vaccine (1992) 10(5):341–344.
   Google Scholar
• PODDA A, CARAPELA DE LUCA E, TITONE L: Acellular pertussis vaccine composed of genetically inactivated pertussis toxin: Safety and immunogenicity in 12- to 24- and 2-to 4-month-old children. Pediatr. (1992) 120(5):680–685.
   Google Scholar
• EDWARDS KM, DECKER MD: Pertussis vaccine. In: Vaccines. Plotkin SA, Orenstein WA (Eds), Saunders, Elsevier, Inc., USA (2004):471–528.
   Google Scholar
• ••The most complete review of pertussisimmunisation, from whole-cell vaccines to acellular vaccines and the new vaccines for use in adolescents and adults, and disease control strategies.
   Google Scholar
• LOCHT C, BERTIN P, MENOZZI FD, RENAULT G: The filamentous haemagglutinin, a multifaceted adhesin produced by virulent Bordetella spp. Microbiol (1993) 9(4):653–660.
   Google Scholar
• EDWARDS KM, MEADE BD, DECKER MD et al: Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics (1995) 96(3):548–557.
   PubMedGoogle Scholar
• ••The main study evaluating theimmunogenicity of acellular pertussis vaccines in comparison with a conventional whole-cell pertussis vaccine.
   Google Scholar
• VAN LOO IHM, VAN DER HEIDE GJ, NAGELKERKE NJD, VERHOEF J, MOOI FR: Temporal trends in the population structure of Bordetella pertussis during 1949-1996 in a highly vaccinated population. J. Infect. Dis. (1999) 179(4):915–923.
   PubMedGoogle Scholar
• HEWLETT EL, CHERRY JD: New and improved vaccines against pertussis. In: New and improved vaccines against pertussis. Levine MM, Woodrow GC, Kaper JB, Cobon GS (Eds), Marcel Dekker, New York, USA (1997):387–416.
   Google Scholar
• KIMURA M, KUNO-SAKAI H: Pertussis vaccines in Japan. Acta Pediatr. Jpn. (1988) 30(2):143–153.
   PubMedGoogle Scholar
• AMERICAN ACADEMY OF PEDIATRICS: Pertussis. In: Red Book: 2003 Report of the Committee on Infectious
   Google Scholar
• •• Diseases Pickering LK (Ed.), American Academy of Pediatrics, Elk Grove Village, IL, USA (2003):472–486.
   Google Scholar
• ROTHSTEIN E, KAMIYA H, Nil R et al: Comparison of diphteria-tetanus-two component acellular pertussis vaccines in United States and japanese infants at 2, 4, and 6 months of age. Pediatrics (1996) 97(2):236–242.
   PubMedGoogle Scholar
• MEDICAL RESEARCH COUNCIL: Vaccination against whooping cough: relation between protection tests in children and results of laboratory tests. Br. Med. J. (1956) 2:454–462.
   PubMedGoogle Scholar
• STORSAETER J, HALLANDER HO, GUSTAFSON L et al.: Levels of antipertussis related to protection after household exposure to Bordetella pertussis. Vaccine (1998) 16(20):1907–1916.
   PubMed Web of Science ®Google Scholar
• STEHR K, CHERRY JD, HEININGER U et al.: A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics (1998) 101(1):1–11.
   PubMedGoogle Scholar
• ENGLUND JA, ANDERSON EL, REED GF et al.: The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunisation with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics (1995) 96(3):580–584.
   PubMedGoogle Scholar
• BELLONI C, DE SILVESTRI A, TINELLI C et al.: Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics (2003) 111(5):1042–1045.
   PubMed Web of Science ®Google Scholar
• DECKER MD, EDWARDS KM, STEINHOFF MC et al.: Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics (1995)96(3 Pt 2):557–566.
   Google Scholar
• ••Controlled comparison of 13 pre-licensedacellular pertusis vaccines and a licensed whole-cell vaccine demonstrating the lower reactogenicity of acellular vaccines.
   Google Scholar
• GRECO D, SALMASO S,MASTRANTONIO P et al.: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl. J. Med. (1996) 334(6):341–348.
   Google Scholar
• ••One of the benchmark trialsdemonstrating efficacy of DTaP vaccines.
   Google Scholar
• GUSTAFSSON L, HALLANDER H, OLIN P, REIZENSTEIN E,STORSAETER J: A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. (1996) 334(6):349–355.
   PubMed Web of Science ®Google Scholar
• ••One of the benchmark trialsdemonstrating efficacy of DTaP vaccines.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Use of diphtheria toxoid-tetanus toxoid-acellular pertussis vaccine as a five dose series: supplemental recommendations of the Advisory Committee on Immunisation Practices (ACIP). MMWR Moth. Mortal. Wkly. Rep. (2000) 49(No. RR-13):1–8.
   Google Scholar
• •Supplementary recommendations of the ACIP about the use of DTaP vaccines as booster doses and data regarding reactogenicity.
   Google Scholar
• SCHMITT HJ, BEUTEL K, SCHUIND A et al: Reactigenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at 14–28 months of age.Pediatr. (1997) 130(4):616–623.
   Google Scholar
• SCHMITT HJ, SCHUIND A, KNUF M et al.: Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants.Pediatr. (1996) 129(5):695–701.
   Google Scholar
• CIOFI DEGLI ATTI ML, OLIN P: Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trial. Dev. Biol. Stand (1997) 89:77–81.
   PubMedGoogle Scholar
• ROSENTHAL S, CHEN R, HADLER S: The safety of acellular pertussis vaccine versus whole-cell pertussis vaccine.A post-marketing assessment. Arch. Pediatr. Adoles. Med. (1996) 150(5):457–460.
   Google Scholar
• DUVERNOY TS, BRAUN MM, and the VAERS WORKING GROUP: Hypotonic-hyporesponsive episodes reported to the Vaccine Adverse Event Reporting System (VAERS) 1996-1998. Pediatrics (2000) 106(4):e52.
   PubMedGoogle Scholar
• •The largest published case series of children with HHE reported to a national vaccine safety surveillance system, supporting a decrease in their notification after introduction of DTaP vaccines.
   Google Scholar
• GOLD M, KEMPE A, OSBOURN M: A comparison of serious adverse reactions to whole-cell and acellular pertussis vaccines in south Australia. Med. J. Aust. (1999) 171(6):331–332.
   PubMedGoogle Scholar
• LE SAUX N, BARROWMAN NJ, MOORE DL, WHITING S,SCHEIFELE D, HALPERIN S: Decrease in hospital admissions for febrile seizures and reports of hypotonic-hyporesponsive episodes presenting to hospital emergency departments since switching to acellular pertussis vaccine in Canada: a report from IMPACT. Pediatrics (2003) 112(5):e348.
   Google Scholar
• AD HOC GROUP FOR THE STUDY OF PERTUSSIS VACCINES: Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet (1988) 1:955–960.
   PubMed Web of Science ®Google Scholar
• STORSAETER J, OLIN P: Relative efficacy of two acellular pertussis vaccine during three years of passive surveillance. Vaccine (1992) 10:142–144.
   PubMedGoogle Scholar
• SALMASO S, MASTRANTONIO P, TROZZI AE et al.: Sustained efficacy during the first 6 years of life of three-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics (2001) 108(5):e81.
   PubMed Web of Science ®Google Scholar
• •Prospective study that estimates the persistence of protection from 3 to 6 years of age of two acellular pertussis vaccines administered as primary immunisation in infancy.
   Google Scholar
• OLIN P, RASMUSSEN F, GUSTAFFSON L et al. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet (1997) 350(9091):1569–1577.
   PubMed Web of Science ®Google Scholar
• ••One of the benchmark trials demonstrating efficacy of DTaP vaccines.
   Google Scholar
• SCHMITT HJ, VON KONIG CH, NEISS A et al: Efficacy of acellular pertussis vaccine in early childhood after household exposure. "AMA (1996) 275(1):37–41.
   PubMed Web of Science ®Google Scholar
• LIESE JG, MESCHIEVITZ CK, HARZER E et al: Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. (1997) 16(11):1038–1044.
   PubMedGoogle Scholar
• TROLLFORS B, TARANGERJ, LAGERGARD T et al.: A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl. J. Med. (1995) 333(16):1045–1050.
   PubMed Web of Science ®Google Scholar
• SIMONDON F, PREZIOSI MP, YAM A et al.: A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine (1997) 15(15):1606–1612.
   PubMed Web of Science ®Google Scholar
• OLIN P, GUSTAFSSON L, BARRETO L et al.: Declining pertussis incidence in Sweden following the introduction of
   Google Scholar
• •• acellular pertussis vaccine. Vaccine (2003) 21(17–18):2015-2021.
   Google Scholar
• CENTERS FOR DISEASE CONTROL AND PREVENTION: Pertussis vaccination: Use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morn. Mortal. Wkly Rep. (1997) 46(RR-7):1–25.
   Google Scholar
• ••Official recommendations on theprevention of pertussis through the use of acellular pertussis vaccines among infants and young children in the US.
   Google Scholar
• SCHMIDT JE, TOZZI AE, RAVA L, GLISMANN S: The EUVAC-NET survey: national pertussis surveillance systems in the European Union, Switzerland, Norway, and Iceland. Eurosurveillance (2001) 6(6):93–112.
   Google Scholar
• TORVALDSEN S, MCINTYRE PB: Effect of the prescool pertussis booster on national notifications of disease in Australia. Pediatr. Infect. Dis. J. (2003) 22(11):956–959.
   PubMedGoogle Scholar
• ZEPP F, SCHMITT HJ, KAUTLIOLD A et al.: Evidence for induction of polysaccharide specific B-cell memory in the 1st year of life: plain Haemophilus influenzae type b-PRP (Hib) boosters children primed with a tetanus-conjugate Hib-DTP-HBV combined vaccine. Eur. Pediam. (1997) 156(1):18–24.
   PubMed Web of Science ®Google Scholar
• CAPIAU C, POOLMAN J, HOET B, BOGAERTS H, ANDRE F: Development and clinical testing of multivalent vaccines based on a diphtheria-tetanus-acellular pertussis vaccine: difficulties encountered and lessons learned. Vaccine (2003) 21(19-20):2273–2287.
   PubMedGoogle Scholar
• •Excellent review on the development process and clinical testing of combined vaccines containing DTaP.
   Google Scholar
• GARNER D, WESTON V: Effectiveness of vaccination for Haemophilus influenzae type b. Lancet (2003) 361(9355):395–396.
   PubMedGoogle Scholar
• http://cisid.who.d1c/VIP/IMM The WHO, Regional Office for Europe — Immunisation Schedules and Coverage.
   Google Scholar
• http://www.nt.who.int/vaccines/globalsumm ary/timeseries/TsincidencePer.htm Pertussis Reported Cases (interactive online data table): WHO, Geneva.
   Google Scholar